Skip to main content

Advertisement

Log in

Mucinous adenocarcinoma, gastric type of the uterine cervix: clinical features and HER2 amplification

Medical Molecular Morphology Aims and scope Submit manuscript

Abstract

Mucinous adenocarcinoma, gastric type (GAS) is difficult to diagnose and shows poor prognosis. Trastuzumab, an anti-human epidermal growth factor type 2 (HER2) monoclonal antibody, is effective in HER2-positive stomach cancer. The objectives of this study were to identify the clinicopathological characteristics of GAS and to evaluate HER2 expression in GAS. We retrospectively reviewed 322 cervical cancer cases diagnosed at the Kyoto University Hospital from 2010 to 2016. The incidence, clinical factors including age, stage, and lymph node status, tumor markers, immunoreactive expression of MUC6, HIK1083, and HER2, and HER2 amplification were evaluated. Of the 322 cases of cervical cancer, 13 cases of the adenocarcinoma cases were diagnosed as GAS. Watery discharge, lower abdominal pain, CA19-9 elevation, and lymph node metastasis were frequently observed in GAS (p = 0.0226, p = 0.0400, p = 0.0346, and p = 0.0274, respectively). Immunohistochemistry showed positive MUC6 status in all 13 cases and positive HIK1083 status in 8 cases. The HER2 expression status was equivocal in six cases by immunohistochemistry and HER2 amplification was identified in one case. GAS exhibits frequent lymph node metastasis and clinical symptoms such as watery discharge and lower abdominal pain, high levels of CA19-9. In addition, some parts of GAS exhibit HER2 amplification.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

References

  1. Mikami Y, McCluggage WG (2013) Endocervical glandular lesions exhibiting gastric differentiation: an emerging spectrum of benign, premalignant, and malignant lesions. Adv Anat Pathol 20:227–237

    Article  PubMed  CAS  Google Scholar 

  2. Baalbergen A (2004) Prognostic factors in adenocarcinoma of the uterine cervix. Gynecol Oncol 92:262–267

    Article  PubMed  CAS  Google Scholar 

  3. Iwasaka T, Fukuda K, Hara K, Yokoyama M, Nakao Y, Uchiyama M, Sugimori H (1998) Neoadjuvant chemotherapy with mitomycin C, etoposide, and cisplatin for adenocarcinoma of the cervix. Gynecol Oncol 70:236–240

    Article  PubMed  CAS  Google Scholar 

  4. Kawakami F, Mikami Y, Kojima A, Ito M, Nishimura R, Manabe T (2010) Diagnostic reproducibility in gastric-type mucinous adenocarcinoma of the uterine cervix: validation of novel diagnostic criteria. Histopathology 56:551–553

    Article  PubMed  Google Scholar 

  5. Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, Lordick F, Ohtsu A, Omuro Y, Satoh T, Aprile G, Kulikov E, Hill J, Lehle M, Ruschoff J, Kang YK, To GATI (2010) Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 376:687–697

    Article  PubMed  CAS  Google Scholar 

  6. Carleton C, Hoang L, Sah S, Kiyokawa T, Karamurzin YS, Talia KL, Park KJ, McCluggage WG (2016) A detailed immunohistochemical analysis of a large series of cervical and vaginal gastric-type adenocarcinomas. Am J Surg Pathol 40:636–644

    Article  PubMed  PubMed Central  Google Scholar 

  7. Kojima A, Mikami Y, Sudo T, Yamaguchi S, Kusanagi Y, Ito M, Nishimura R (2007) Gastric morphology and immunophenotype predict poor outcome in mucinous adenocarcinoma of the uterine cervix. Am J Surg Pathol 31:664–672

    Article  PubMed  Google Scholar 

  8. Pecorelli S, Zigliani L, Odicino F (2009) Revised FIGO staging for carcinoma of the cervix. Int J Gynaecol Obstet 105:107–108

    Article  PubMed  Google Scholar 

  9. Mikami Y, Minamiguchi S, Teramoto N, Nagura M, Haga H, Konishi I (2013) Carbonic anhydrase type IX expression in lobular endocervical glandular hyperplasia and gastric-type adenocarcinoma of the uterine cervix. Pathol Res Pract 209:173–178

    Article  PubMed  CAS  Google Scholar 

  10. Yu J, Zheng W (2016) An alternative method for screening gastric cancer based on serum levels of CEA, CA19-9, and CA72-4. J Gastrointest Cancer 49(1):57–62. https://doi.org/10.1007/s12029-016-9912-7

    Article  CAS  Google Scholar 

  11. Kusanagi Y, Kojima A, Mikami Y, Kiyokawa T, Sudo T, Yamaguchi S, Nishimura R (2010) Absence of high-risk human papillomavirus (HPV) detection in endocervical adenocarcinoma with gastric morphology and phenotype. Am J Pathol 177:2169–2175

    Article  PubMed  PubMed Central  Google Scholar 

  12. Kido A, Mikami Y, Koyama T, Kataoka M, Shitano F, Konishi I, Togashi K (2014) Magnetic resonance appearance of gastric-type adenocarcinoma of the uterine cervix in comparison with that of usual-type endocervical adenocarcinoma: a pitfall of newly described unusual subtype of endocervical adenocarcinoma. Int J Gynecol Cancer 24:1474–1479

    Article  PubMed  Google Scholar 

  13. Takatsu A, Shiozawa T, Miyamoto T, Kurosawa K, Kashima H, Yamada T, Kaku T, Mikami Y, Kiyokawa T, Tsuda H, Ishii K, Togashi K, Koyama T, Fujinaga Y, Kadoya M, Hashi A, Susumu N, Konishi I (2011) Preoperative differential diagnosis of minimal deviation adenocarcinoma and lobular endocervical glandular hyperplasia of the uterine cervix: a multicenter study of clinicopathology and magnetic resonance imaging findings. Int J Gynecol Cancer 21:1287–1296

    PubMed  Google Scholar 

  14. Stolnicu S, Barsan I, Hoang L, Patel P, Chiriboga L, Terinte C, Pesci A, Aviel-Ronen S, Kiyokawa T, Alvarado-Cabrero I, Pike MC, Oliva E, Park KJ, Soslow RA (2018) Diagnostic algorithmic proposal based on comprehensive immunohistochemical evaluation of 297 invasive endocervical adenocarcinomas. Am J Surg Pathol. https://doi.org/10.1097/PAS.0000000000001090

    Article  PubMed Central  PubMed  Google Scholar 

  15. Park KJ, Kiyokawa T, Soslow RA, Lamb CA, Oliva E, Zivanovic O, Juretzka MM, Pirog EC (2011) Unusual endocervical adenocarcinomas: an immunohistochemical analysis with molecular detection of human papillomavirus. Am J Surg Pathol 35:633–646

    Article  PubMed  Google Scholar 

  16. Nucci MR, Clement PB, Young RH (1999) Lobular endocervical glandular hyperplasia, not otherwise specified: a clinicopathologic analysis of thirteen cases of a distinctive pseudoneoplastic lesion and comparison with fourteen cases of adenoma malignum. Am J Surg Pathol 23:886–891

    Article  PubMed  CAS  Google Scholar 

  17. Mikami Y, Kiyokawa T, Hata S, Fujiwara K, Moriya T, Sasano H, Manabe T, Akahira J, Ito K, Tase T, Yaegashi N, Sato I, Tateno H, Naganuma H (2004) Gastrointestinal immunophenotype in adenocarcinomas of the uterine cervix and related glandular lesions: a possible link between lobular endocervical glandular hyperplasia/pyloric gland metaplasia and ‘adenoma malignum’. Mod Pathol 17:962–972

    Article  PubMed  Google Scholar 

  18. Nara M, Hashi A, Murata S, Kondo T, Yuminamochi T, Nakazawa K, Katoh R, Hoshi K (2007) Lobular endocervical glandular hyperplasia as a presumed precursor of cervical adenocarcinoma independent of human papillomavirus infection. Gynecol Oncol 106:289–298

    Article  PubMed  Google Scholar 

  19. Tsuji T, Togami S, Nomoto M, Higashi M, Fukukura Y, Kamio M, Yonezawa S, Douchi T (2011) Uterine cervical carcinomas associated with lobular endocervical glandular hyperplasia. Histopathology 59:55–62

    Article  PubMed  Google Scholar 

  20. Nishio S, Tsuda H, Fujiyoshi N, Ota S, Ushijima K, Sasajima Y, Kasamatsu T, Kamura T, Matsubara O (2009) Clinicopathological significance of cervical adenocarcinoma associated with lobular endocervical glandular hyperplasia. Pathol Res Pract 205:331–337

    Article  PubMed  Google Scholar 

  21. Karamurzin YS, Kiyokawa T, Parkash V, Jotwani AR, Patel P, Pike MC, Soslow RA, Park KJ (2015) Gastric-type endocervical adenocarcinoma: an aggressive tumor with unusual metastatic patterns and poor prognosis. Am J Surg Pathol 39:1449–1457

    Article  PubMed  PubMed Central  Google Scholar 

  22. Park YS, Hwang HS, Park HJ, Ryu MH, Chang HM, Yook JH, Kim BS, Jang SJ, Kang YK (2012) Comprehensive analysis of HER2 expression and gene amplification in gastric cancers using immunohistochemistry and in situ hybridization: which scoring system should we use? Hum Pathol 43:413–422

    Article  PubMed  CAS  Google Scholar 

  23. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL (1987) Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235:177–182

    Article  PubMed  CAS  Google Scholar 

  24. Kurokawa Y, Matsuura N, Kimura Y, Adachi S, Fujita J, Imamura H, Kobayashi K, Yokoyama Y, Shaker MN, Takiguchi S, Mori M, Doki Y (2015) Multicenter large-scale study of prognostic impact of HER2 expression in patients with resectable gastric cancer. Gastric Cancer 18:691–697

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Ken Yamaguchi.

Ethics declarations

Conflict of interest

The authors declare that they have no conflicts of interest.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary material 1 (DOCX 26 KB)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Nakamura, A., Yamaguchi, K., Minamiguchi, S. et al. Mucinous adenocarcinoma, gastric type of the uterine cervix: clinical features and HER2 amplification. Med Mol Morphol 52, 52–59 (2019). https://doi.org/10.1007/s00795-018-0202-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00795-018-0202-2

Keywords

Navigation